Quantity of qualified sufferers: CDEC discussed the uncertainty in the amount of clients with moderately serious to significant hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical experts consulted by CADTH indicated that some patients who are classified as having moderate or reasonable condition could have a severe bleeding phenotype, https://anciush691cfd5.smblogsites.com/profile